Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Condition(s):Gastric Cancer; Gastroesophageal Junction AdenocarcinomaLast Updated:December 14, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Gastric Cancer; Gastroesophageal Junction AdenocarcinomaLast Updated:December 14, 2023Recruiting
Condition(s):Metastatic MelanomaLast Updated:September 6, 2022Recruiting
Condition(s):Subarachnoid Hemorrhage; Subarachnoid Hemorrhage, Aneurysmal; Vasospasm, Cerebral; Aneurysmal Subarachnoid HemorrhageLast Updated:December 14, 2022Recruiting
Condition(s):Neuroendocrine CarcinomaLast Updated:April 14, 2021Recruiting
Condition(s):Sinusoidal Obstruction Syndrome; Veno-occlusive DiseaseLast Updated:March 26, 2024Recruiting
Condition(s):Stroke, Ischemic; Stroke, AcuteLast Updated:January 30, 2024Recruiting
Condition(s):Knee Arthroplasty, TotalLast Updated:December 29, 2023Recruiting
Condition(s):ShockLast Updated:August 30, 2023Recruiting
Condition(s):Metastatic Pancreatic CancerLast Updated:September 28, 2023Recruiting
Condition(s):Hodgkin Lymphoma; Classic Hodgkin Lymphoma; Relapsed Classical Hodgkin Lymphoma; Refractory Classic Hodgkin LymphomaLast Updated:February 21, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.